1. Introduction {#sec1}
===============

Tulsi in Hindi or Tulasi in Sanskrit (holy basil in English) is a highly revered culinary and medicinal aromatic herb from the family Lamiaceae that is indigenous to the Indian subcontinent and been used within Ayurvedic medicine more than 3000 years. In the Ayurveda system tulsi is often referred to as an "Elixir of Life" for its healing powers and has been known to treat many different common health conditions. In the Indian Materia Medica*tulsi* leaf extracts are described for treatment of bronchitis, rheumatism, and pyrexia \[[@B1]\]. Other reported therapeutic uses include treatment of epilepsy, asthma or dyspnea, hiccups, cough, skin and haematological diseases, parasitic infections, neuralgia, headache, wounds, and inflammation \[[@B2]\] and oral conditions \[[@B3]\]. The juice of the leaves has been applied as a drop for earache \[[@B4]\], while the tea infusion has been used for treatment of gastric and hepatic disorders \[[@B5]\]. The roots and stems were also traditionally used to treat mosquito and snake bites and for malaria \[[@B5]\].

Three types of tulsi are commonly described.*Ocimum tenuiflorum* (or*Ocimum sanctum* L.) includes 2 botanically and phytochemically distinct cultivars that include Rama or Sri tulsi (green leaves) and Krishna or Shyama tulsi (purplish leaves) \[[@B6], [@B7]\], while*Ocimum gratissimum* is a third type of tulsi known as Vana or wild/forest tulsi (dark green leaves) \[[@B8], [@B9]\]. The different tulsi types exhibit vast diversity in morphology and phytochemical composition including secondary metabolites, yet they can be distinguished from other*Ocimum* species by the colour of their yellow pollen, high levels of eugenol \[[@B10]\], and smaller chromosome number \[[@B11]\]. Despite being distinct species with*Ocimum tenuiflorum* having six times less DNA than*Ocimum gratissimum* \[[@B11]\], they are traditionally used in the same way to treat similar ailments \[[@B5]\]. For consistency, this review uses the term tulsi to refer to both*Ocimum tenuiflorum* or*Ocimum gratissimum*.

Tulsi has been the subject of numerous scientific studies and its pharmacological and wide range of therapeutic applications are the subject of more than one hundred publications during the last decade alone. Numerous in vitro and animal studies attest to tulsi leaf having potent pharmacological actions that include adaptogenic \[[@B12]--[@B14]\], metabolic \[[@B15]--[@B17]\], immunomodulatory \[[@B18]--[@B20]\], anticancer \[[@B21]--[@B23]\], anti-inflammatory \[[@B24], [@B25]\], antioxidant \[[@B26], [@B27]\], hepatoprotective \[[@B28], [@B29]\], radioprotective \[[@B30], [@B31]\], antimicrobial \[[@B32]--[@B35]\], and antidiabetic effects \[[@B36]--[@B38]\] that have been extensively reviewed previously \[[@B39]--[@B45]\].

Preclinical studies have demonstrated that tulsi increases swimming survival times in mice and prevents stress-induced ulcers in rats \[[@B46]\] with antistress effects comparable to antidepressant drugs \[[@B47]\]. Similarly, recent studies report leaf extracts from ethanolic and aqueous tulsi protects rats from stress-induced cardiovascular changes \[[@B48], [@B49]\]. Studies in animal models have further shown that the leaf extract of tulsi possesses anticonvulsant and anxiolytic activities \[[@B50], [@B51]\]. Several animal studies conducted over the past fifty years report that ingestion of tulsi leaves improves both glucose and lipid profiles in normal and diabetic-induced animal models \[[@B36], [@B38], [@B52]--[@B58]\]. Tulsi aqueous leaf extract intramammary infusion has also showed promising effect on improving the immune response in bovine models \[[@B59]\].

In addition to the extensive literature documenting in vitro and animal research, studies on the use of tulsi as part of a polyherbal formulation in humans has been systematically reviewed \[[@B60]\]. To date, however, there are no systematic reviews on the clinical efficacy and safety of tulsi as a single herbal intervention in humans. The objective of this review was therefore to summarize and critically appraise human clinical trials of tulsi in order to assess the current evidence on tulsi\'s clinical efficacy and safety.

2. Methods and Materials {#sec2}
========================

2.1. Search Strategies {#sec2.1}
----------------------

Relevant clinical studies were identified through searching PubMed, Google Scholar, ScienceDirect, Medline, Embase, Cochrane Library, and Indian Medical databases. The terms in the title or abstract (MeSH and free search terms) alone or in combination searched were "Tulsi", "Tulasi", "Holy Basil", "ocimum sanctum", "Ocimum tenuiflorum", "Ocimum gratissimum", "ocimum", "Albahaca Morada" or combined with "clinical trial", "clinical", or "human".

2.2. Inclusion Criteria {#sec2.2}
-----------------------

Studies were included if they reported on a human intervention study that involved ingestion of any form of tulsi or holy basil (*Ocimum sanctum* or*Ocimum tenuiflorum* or*Ocimum gratissimum*) and at least one clinical outcome.

2.3. Exclusion Criteria {#sec2.3}
-----------------------

Studies were excluded if they were reviews, were nonclinical studies, did not involve human subjects, did not report a biological outcome, only involved topical application or only used tulsi at part of a polyherbal formulation, and did not report on the use of tulsi as a single herbal intervention.

2.4. Study Selection {#sec2.4}
--------------------

All the titles and abstracts were screened on the basis of the predetermined inclusion and exclusion criteria described above. The full text of each article was reviewed to assess suitability of the study with duplications removed. The search included clinical studies written in the English language and articles from inception until November 2016 in the above-mentioned electronic databases. The references of selected articles were manually searched to identify further relevant studies and, where appropriate, study authors were contacted to request further information.

2.5. Quality Assessment {#sec2.5}
-----------------------

In order to evaluate the quality of design and implementation of trials, information was collected on the study design, randomization, blinding, and description of participant dropouts and the Jadad scale was used to assess methodological quality \[[@B61]\].

2.6. Data Extraction {#sec2.6}
--------------------

Eligible studies were reviewed with the following data extracted and tabulated: (1) first author name and year of publication; (2) design of the study; (3) Jadad score; (4) study participants (intervention and control groups); (5) extraction method; (6) duration of intervention; (7) tulsi dose and dose form (8) comparator; (9) outcome measure(s) including both primary and secondary, and (10) any adverse event(s).

3. Results {#sec3}
==========

3.1. Study Description {#sec3.1}
----------------------

After screening 1553 studies, a total of 31 articles on tulsi met the inclusion criteria. Four articles were excluded due to being inaccessible and one article reported two independent clinical studies, while one clinical trial was reported in three separate articles. This left a total of 24 independent clinical studies to be reviewed. A flow chart of the systematic search and study selection protocol is presented in [Figure 1](#fig1){ref-type="fig"}.

The reviewed studies involved a total of 1111 participants with ages ranging from 10 to 80 years old with eight clinical trials limiting participants to ≥40 years old \[[@B38], [@B62], [@B63], [@B64]--[@B66], [@B68], [@B67]\]. Only three clinical trials included 100 or more participants \[[@B70], [@B63], [@B69]\]. The study durations ranged from 2 to 13 weeks and tulsi dosage and frequency varied from 300 mg to 3000 mg given as 1--3 times per day as tulsi leaf aqueous extract; 300 mg--1000 mg once or twice per day as tulsi leaf ethanolic extract; 6 g to 14 g per day as the tulsi whole plant aqueous extract; and 10 g fresh tulsi leaf aqueous extract administered as once or four equal doses daily, and as tincture solution 30 drops a day were administered as three equal doses daily.

From the 24 studies identified only eight included a placebo \[[@B63], [@B64], [@B66], [@B67]--[@B72], [@B71], [@B69]\]. Five of the included trials adopted a two-arm parallel design \[[@B74], [@B75], [@B70], [@B76], [@B77]\], while four used a cross-over design with one being described in three different papers that reported on two different sets of outcomes \[[@B66], [@B67], [@B72]\].

Included studies were classified according to three major clinical domains: metabolic related disorders; immunity; and neurocognitive function (Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}). Only two studies described the type of tulsi (Krishna) used while all other papers referred to tulsi as*Ocimum sanctum* \[[@B78], [@B68]\] not distinguishing between cultivars. Four studies reported on the use of tulsi alone and along with food, hypoglycemic drug, curry or Neem \[[@B75], [@B76], [@B65], [@B73]\]. Most studies looked at clinical populations with specific acute or chronic illnesses, such as viral infection, psychological stress, diabetes, or metabolic syndrome, with only three studies reporting on the effects of tulsi in healthy human participants \[[@B79], [@B73], [@B71]\].

3.2. Effectiveness and Safety Evaluation {#sec3.2}
----------------------------------------

The most common outcome measurements were related to blood glucose levels (8 studies), lipid profile (6 studies), blood pressure (6 studies), immune response (6 studies), and neurocognitive changes (4 studies). Other outcomes included mood (3 studies), fatigue (2 studies), uric acid levels (2 studies), diabetes secondary symptoms (1 study), and sleep (1 study). Fifteen of the 24 included studies reported no adverse events and eight studies did not describe or refer to any adverse events. Only one study that used tulsi leaf extract as 250 mg capsule taken before meals twice daily in 16 obese adults reported the occurrence of occasional nausea.

3.3. Quality Assessment {#sec3.3}
-----------------------

The studies were classified as either Randomized Clinical Trial Placebo Controlled (RCT-PC 6), Randomized Clinical Trials with no placebo (RCT 7), or Clinical Trials where no information on randomization or control was available (CT 6). Only three out of 24 studies, two of which examined neurocognitive effects \[[@B71], [@B69]\] and one reported on immunity as well as cardiovascular changes \[[@B79], [@B72]\], were rated as high quality with Jadad scores of 4-5 points, with the remaining studies varying in quality with Jadad scores ranging from 0 to 3 points. The score for each included study is presented in Tables [1](#tab1){ref-type="table"}[](#tab2){ref-type="table"}--[3](#tab3){ref-type="table"}.

3.4. Metabolic Disorders {#sec3.4}
------------------------

Seventeen clinical trials reported on metabolic conditions with ten studies reporting on type 2 diabetes or metabolic syndrome with measures of blood glucose, lipids, and blood pressure, yet only one study reported on the clinical symptoms associated with type 2 diabetes such as polydipsia, polyphagia, polyuria, sweating, fatigue, burning feet, itching, and headache \[[@B65]\]. In addition one study reported on obesity \[[@B74]\] and two studies on uric acid changes in participants with gouty arthritis \[[@B38], [@B70]\].

Six of the identified trials on metabolic conditions were randomized clinical trials with placebo controls \[[@B63], [@B64], [@B66], [@B79], [@B67]\]. In addition, eight studies were of 2--5 weeks duration \[[@B38], [@B75], [@B80], [@B66], [@B81]--[@B67]\], three were of 6--8 weeks \[[@B62], [@B74], [@B64]\], and six were of 12-13 weeks \[[@B70]--[@B76], [@B65], [@B78], [@B68]\]. When the duration of the tulsi intervention was increased from 4-5 weeks \[[@B38], [@B66]\] to 12-13 weeks there was a more dramatic reduction in fasting blood glucose (FBG) and postprandial glucose (PPG) compared to controls \[[@B63], [@B76]\]. In particular, HbA1c (35.8%) significantly decreased when tulsi was added as adjunct therapy to hypoglycemic medication compared to drug medication alone \[[@B76]\].

The earliest clinical trial conducted in 1964 with 10 patients with type 2 diabetes reported that over a period of 12 weeks, a 14 g decoction of whole Krishna tulsi plant led to a gradual improvement in fasting blood glucose in 9 out of 10 patients \[[@B78]\]. Three decades later, the first randomized placebo-controlled clinical trial reported daily ingestion of 2.5 g of tulsi leaves led to significant improvements of FBG, PPG, and urine glucose in type 2 diabetes patients after 4 weeks \[[@B66]\]. In addition, Rai et al. reported that 4 weeks of supplementation with tulsi powder significantly lowered blood glucose and glycated proteins, reduced uric acid levels, and improved lipid profiles in participants with type 2 diabetes \[[@B38]\]. In comparable trials with longer durations, FBG and PPG improved by 1.2--2.2 and 1.5--6.0 folds, respectively, while HbA1c improved 1.5 and 3.2 fold after 12-13 weeks \[[@B63], [@B76]\]. Similarly, lipid profile was improved significantly in MetS and diabetes participants in three clinical trials \[[@B38], [@B63], [@B64]\] with a separate clinical trial reporting significant improvement in lipid profile in obese participants \[[@B74]\] and a further study reporting improved lipid levels in healthy subjects \[[@B79]\].

A further 12-week study of type 2 diabetes patients reported greater improvement in both blood glucose and HbAc1 levels when 300 mg of tulsi leaf extract was administered along with the antidiabetic drug glibenclamide, compared to drug treatment alone \[[@B76]\]. Similarly, a controlled trial of patients with diabetes found that consumption of 2 g of tulsi powdered leaves, either alone or combined with curry leaves, led to significant improvement in blood sugars after two weeks \[[@B75]\]. In a further 12-week randomized trial in diabetic patients, 2 g of tulsi leaf extract alone or combined with neem leaf extract produced marked reduction in diabetic symptoms with greatest effect noted for the combination \[[@B65]\].

Six trials reported on the effect of tulsi on individual features of metabolic syndrome \[[@B74], [@B68]--[@B67]\]. Two studies reported significant improvement of blood pressure in hypertensive participants given 30 mL of fresh tulsi leaf juice once daily or 30 mL twice a day for 10 and 12 days, respectively \[[@B67]\], with a further study reporting normalisation of blood pressure in hypotensive adult females \[[@B81]\]. Yet another study reported improvement in serum lipids with no difference in blood pressure in healthy adults administered 300 mg per day of tulsi leaf ethanolic extract for 4 weeks \[[@B79]\]. A further study reported improved lipid profiles in older adults (60--80 years) with psychosomatic symptoms after administration of 3 g of whole plant tulsi extract twice daily for 12 weeks \[[@B68]\]. A more recent study also reported improvement in lipid profiles, as well as BMI of obese participants administered 250 mg capsules of tulsi leaf extract twice daily for 8 weeks \[[@B74]\].

3.5. Immunomodulation and Inflammation {#sec3.5}
--------------------------------------

Enhanced immune response was reported in five clinical studies \[[@B73]--[@B77]\]. A small randomized double-blind, and placebo-controlled trial found increased immune response with increased Natural Killer (NK) and T-helper cells in healthy adult participants compared to placebo volunteers after 4 weeks of 300 mg or ethanolic tulsi leaf extract daily taken before food \[[@B72]\]. Another 2-week controlled randomized study in which young adult volunteers were provided with nutrition bars fortified with 1 g of ethanolic tulsi leaf extract found that compared to control participants, the intervention group had significantly improved VO~2~ max, less fatigue, reduced Creatine Kinase, and improved immune response to viral infection as indicated by reduced load of human herpesvirus 6 in saliva \[[@B73]\].

Two clinical trials studied the effect of daily administration of 10 g of an aqueous extract of fresh tulsi leaves in patients with acute viral infections, with a study on patients with acute viral encephalitis reporting increased survival after 4 weeks in the tulsi group compared to a group given dexamethasone and a study on viral hepatitis reporting symptomatic improvement after 2 weeks \[[@B83], [@B77]\]. A further study of asthmatic patients found that 500 mg of dried tulsi leaves taken three times daily improved vital capacity and provided relief of asthmatic symptoms within 3 days \[[@B82]\].

3.6. Neurocognitive Effect {#sec3.6}
--------------------------

The four studies that reported on neurocognitive effects all showed significant improvements in mood and/or cognitive function regardless of age, gender, formulation, dose, or quality of the study \[[@B68], [@B71]--[@B84]\]. Cognition function was assessed in a randomized, placebo-controlled, clinical trial that demonstrated an improvement in cognitive flexibility, short-term memory, and attention in 40 healthy young adults (17--30 years) following treatment with 300 mg daily tulsi for 4 weeks \[[@B71]\]. However, the cognitive effects of tulsi were only significant after the first two weeks compared to the placebo, with no significant difference found in stress levels. This is in contrast to three clinical studies that reported significant reduction in anxiety and stress levels with higher doses of tulsi given over a longer time period \[[@B68], [@B69], [@B84]\]. The positive effect of tulsi on mood was demonstrated in three studies, with two studies reporting reductions of 31.6%--39% in overall stress-related symptoms in patients with psychosomatic problems compared to a control group \[[@B69], [@B84]\].

4. Discussion {#sec4}
=============

Despite a long history of traditional use and widespread availability, relatively few human intervention studies have been conducted on the effectiveness of tulsi for clinical conditions and this is the first comprehensive literature review of published human research on the ingestion of tulsi as a single herbal intervention. The studies identified in this review could be classified according to three main clinical domains including metabolic disorders (15 studies), neurocognitive or mood conditions (4 studies), and immunity and infections (5 studies), which are all extremely relevant to the growing world-wide epidemic of lifestyle-related chronic disease. The finding that the reviewed studies reported favourable clinical effects across these domains suggests that tulsi may indeed be an effective adaptogen that has a role in helping to address the psychological, physiological, immunological, and metabolic stresses of modern living.

It is interesting that tulsi has important clinical effects across diverse therapeutic domains, all of which may have inflammation as an underlying factor. The anti-inflammatory effects of tulsi have been previously documented in many in vitro and in vivo studies \[[@B43], [@B85]--[@B88]\], and it is likely that tulsi has multiple bioactive secondary metabolites that act alone or synergistically to inhibit inflammatory pathways. There is also evidence to suggest that tulsi may be useful as an adjunct to pharmacotherapy and nutrition in the treatment of metabolic disorders thereby reducing the need for high doses of drugs, which may have adverse effects. The clinical effects demonstrated in the reviewed studies suggest tulsi may have an important role in addressing other inflammatory disorders and that the Ayurvedic tradition of consuming tulsi on a daily basis may be an effective lifestyle measure to address many modern chronic diseases.

The most commonly used part of the tulsi plant is the leaf (dried or fresh), which is known to contain several bioactive compounds including eugenol, ursolic acid, *β*-caryophyllene, linalool, and 1,8-cineole \[[@B89]--[@B91]\]. Eugenol has been found to be the major bioactive metabolite common to all three tulsi varieties with varying amounts in each cultivar \[[@B92], [@B93]\] and it has recently been suggested to act via dual cellular mechanisms to lower blood glucose levels. These include competitively preventing the binding of glucose to serum albumin and inhibiting the conversion of complex carbohydrate to glucose \[[@B93]\]. However, while eugenol has been shown to be bioactive, the phytochemical composition of tulsi is very complex and varies depending on different conditions \[[@B94]--[@B97]\] and there are many other potential active secondary metabolites such as other phenylpropanoids (methyl eugenol, rosmarinic acid), monoterpenes (ocimene), and sesquiterpenes (germacrene) that could alone or synergistically produce therapeutic benefits \[[@B98]\].

All reviewed studies reported favourable clinical effects with minimal or no side effects irrespective of dose, formulation, or the age or gender of participants, with only one clinical trial reporting transient mild nausea \[[@B74]\]. As the longest study was only 13 weeks, the failure to report any adverse effects does not preclude the presence of any long term side effects; however, the long traditional history of regular tulsi use suggests any serious long term effects are unlikely and that daily ingestion of tulsi is safe. Furthermore, the results of this review are consistent with previous evidence for the clinical efficacy and safety of tulsi, which includes multiple in vitro and in vivo studies and many human clinical trials in addition to traditional use.

4.1. Limitations and Scope {#sec4.1}
--------------------------

This review, which comprehensively reviewed all human clinical trials published in English language on ingestion of tulsi as a single herb, has many limitations. While the review included 24 studies and minimized bias by using a systematic and independent search strategy without limiting publication year or study design, we cannot be certain that all studies were located; this is especially due to the fact that almost all studies were conducted in India and published in local journals, some of which are very difficult to access or search. There may also be unpublished studies that report negative outcomes \[[@B99]\]. Furthermore, while the reviewed studies were consistent in reporting positive effects of tulsi in humans, only 7 out of 24 can be considered high quality studies with all but three failing to include a double-blind strategy. Tulsi\'s therapeutic effects may have therefore been overestimated and while the efficacy of tulsi was reported across a wide range of formulations and doses, many studies also failed to provide details of the cultivar, dosage form, or specific dosage or quality control measures of the tulsi used.

This review suggests that tulsi is an example of the Ayurvedic holistic lifestyle approach to health and appears to provide a vast array of health benefits that offers solutions to many modern day health problems. While the reviewed studies could be classified into three major therapeutic domains, there is insufficient evidence for any specific tulsi formulation to assist in any one condition. More rigorous studies with larger sample sizes and longer durations and standardised formulations are therefore needed before specific recommendations can be made for the treatment of any specific disease. This review further highlights the need to investigate and determine unique signature compounds specific to each of the three tulsi varieties, to not only identify the bioactive metabolites that may synergistically interact, but also shed light on the underlying mechanism of action on metabolic and inflammatory pathways.

5. Conclusion {#sec5}
=============

Despite the lack of large-scale or long term clinical trials on the effect of tulsi in humans, the findings from 24 human studies published to date suggest that the tulsi is a safe herbal intervention that may assist in normalising glucose, blood pressure and lipid profiles, and dealing with psychological and immunological stress. Furthermore, these studies indicate the daily addition of tulsi to the diet and/or as adjunct to drug therapy can potentially assist in prevention or reduction of various health conditions and warrants further clinical evaluation.
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###### 

Effect of tulsi on metabolic related-disorders in human clinical trials.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical\                                     Authors\                          Study design     Jadad\            Participants^*∗∗*^ (age range)   Tulsi\               Intervention         Comparator         Outcome\                       Adverse\                     
  domain                                        (year)                                             score                                              extract                                                      measure(s)                     events (s)                   
  --------------------------------------------- --------------------------------- ---------------- ----------------- -------------------------------- -------------------- -------------------- ------------------ ------------------------------ ---------------------------- ----------
  Metabolic disorders                           Gandhi et al. (2016) \[[@B62]\]   Randomized\      **1**             40 male adults\                  Tulsi leaves\        6.5 weeks            3 g/day\           Not\                           Significant↓ postprandial\   Not\
                                                                                  controlled\                        T2DM\                            caps                                      before meal        disclosed                      glucose & fasting blood\     reported
                                                                                  clinical trial                     (45--55 years)                                                                                                               glucose                      

  Satapathy et al. (2016) \[[@B74]\]            Randomized\                       **3**            30 adults\        Tulasi^1^  \                     8 weeks              250 mg/day\          Parallel group\    Improved BMI, lipid profile\   Mild\                        
                                                parallel group\                                    Obesity\          leaves\                                               2x daily\            no intervention    (except TC), TG & IR           nausea                       
                                                clinical trial                                     (17--30 years)    caps                                                  before meal                                                                                         

  Venkatesan and Sengupta (2015) \[[@B75]\]     Clinical trial\                   **0**            30 adults\        Tulsi powder\                    2 weeks              2 g/day              Curry leaves\      Significant↓ post-prandial\    Not\                         
                                                controlled\                                        T2DM              leaves                                                                     tulsi + curry      glucose & fasting blood        reported                     
                                                parallel group                                                                                                                                                                                                                 

  Srinivasa Prasadacharyulu (2014) \[[@B80]\]   Clinical study\                   **0**            3 adults\         Fresh tulsi\                     5 weeks              fresh leaves^3^  \   None               Considerable decrease in\      None                         
                                                case report                                        T2DM              leaves                                                3x daily                                blood glucose reaching\                                     
                                                                                                                                                                                                                   near normal levels                                          

  Ahmad et al. (2013) \[[@B70]\]                Randomized\                       **2**            200 adults\       Tincture^2^  \                   12 weeks             10 drops\            Tincture\          Significant reduction in\      Not\                         
                                                single-blind\                                      Gouty\            from tulsi                                            3 times/day          wild rosemary\     serum uric acid                reported                     
                                                parallel group                                     Arthritis                                                                                    10 drops × 3/day                                                               

  Devra et al. (2012) \[[@B63]\]                Randomized,\                      **1**            100 adults\       Aqueous\                         12 weeks             5 mL/×2 day\         Not\               Improved lipid profile,\       Not\                         
                                                placebo-controlled\                                MetS\             tulsi Leaves                                          before meals         disclosed          fasting blood glucose,\        reported                     
                                                clinical trial                                     (≥40 years)                                                                                                     and BP                                                      

  Somasundaram et al. (2012) \[[@B76]\]         Randomized,\                      **1**            60 adults\        Tulsi leaves +\                  13 weeks             300 mg/day tulsi\    5 mg/day\          Significant ↓fasting blood\    None                         
                                                controlled parallel\                               T2DM\             glibenclamide\                                        + 5 mg\              glibenclamide      & postprandial glucose\                                     
                                                clinical Trial                                     (30--65 years)    drug                                                  Glibenclamide                           reduced HBA1c                                               

  Dineshkumar et al. (2010) \[[@B64]\]          Randomized\                       **3**            40 adults\        Aqueous\                         8 weeks              500 g/day            Water              Significant improvement\       None                         
                                                placebo-controlled\                                T2DM\             tulsi leaves                                                                                  in lipid profile                                            
                                                clinical trial                                     (45--55 years)                                                                                                                                                              

  Kochhar et al. (2009) \[[@B65]\]              Randomized,\                      **1**            90 male adults\   Powder\                          12 weeks             2 g/day              Neem\              Improved T2DM\                 Not\                         
                                                clinical trial                                     T2DM/MetS\        tulsi leaves                                                               neem + tulsi       symptoms: ↓polydipsia,\        reported\                    
                                                                                                   (40--60 years)                                                                                                  ↓polyphagia, & BP                                           

  Rai et al. (1997) \[[@B38]\]                  Clinical trial\                   **1**            27 adults\        Tulsi\                           4 weeks              1 g/day\             None               Improved lipid profile,\       Not\                         
                                                controlled group                                   T2DM/MeS\         powder\                                               in morning\                             blood glucose, glycated\       reported                     
                                                                                                   (45--65 years)    leaves                                                before meal                             proteins (HbA1c) & UA                                       

  Agrawal et al. (1996) \[[@B66]\]              Randomized,\                      **1**            40 adults\        Tulsi\                           5 weeks\             2.5 g/day\           Spinach\           Significant ↓fasting blood\    None                         
                                                single-blind,\                                     T2DM\             powder\                          (+5-day wash out)    in morning\          powder\            glucose, post-prandial\                                     
                                                Placebo-controlled\                                (41--65 years)    leaves                                                before meal          leaves\            glucose and urine glucose                                   
                                                cross-over                                                                                                                                      2.5 g/day                                                                      

  Luthy (1964) \[[@B78]\]                       Clinical trial                    **1**            10 adults\        Whole plant\                     12 weeks             14 g/day             None               Reduced blood glucose\         None                         
                                                                                                   T2DM              decoction                                                                                     in 9 T2DM adults                                            

  Verma et al. (2012) \[[@B68]\]                Clinical trial                    **0**            5 adults\         Powder\                          12 weeks             3 g × 2/day          None               Significant improvement\       None                         
                                                                                                   psychosomatic\    whole plant\                                                                                  in lipid profile                                            
                                                                                                   (60--80 years)    tulsi                                                                                                                                                     

  Bhargava et al., (2013) \[[@B81]\]            Clinical study\                   **1**            50 Female\        Fresh juice\                     4 weeks              Juice × 2/day        None               Significant changes,\          Not\                         
                                                open label                                         adults\           15 tulsi\                                                                                     in Blood pressure              reported                     
                                                                                                   hypotensive\      leaves                                                                                                                                                    
                                                                                                   (18--30 years)                                                                                                                                                              

  Mondal et al. (2012) \[[@B79]\]               Randomized,\                      **5**            22 healthy\       Ethanolic\                       4 weeks\             300 mg/day\          300 mg/day\        Reduction in lipid profile,\   None                         
                                                double-blind,\                                     adults\           tulsi                            (+3-week wash-out)   before food          sucrose            in 6 participants                                           
                                                placebo-controlled\                                (22--37 years)                                                                                                                                                              
                                                cross-over\                                                                                                                                                                                                                    
                                                leaves                                                                                                                                                                                                                         

  Sarvaiya (1986) \[[@B67]\]                    Randomized\                       **1**            20 adults,\       Fresh Juice\                     10 days\             30 mL/day            Green colored\     Significant ↓blood pressure    None                         
                                                placebo controlled\                                hypertension\     75% tulsi                        (+5-day wash-out)                         water 30 mL/day\                                                               
                                                cross-over                                         (45--64 years)                                                                               before meal                                                                    

  Sarvaiya (1986) \[[@B67]\]                    Randomized\                       **1**            16 adults,\       Fresh Juice\                     12 days              30 mL\               Green-colored\     Significant ↓blood pressure\   None                         
                                                placebo-controlled                                 hypertension\     75% tulsi                                             2 times a day\       water\             (lowered by 25%)                                            
                                                                                                   (45--64 years)                                                          before meals         30 mL × 2/day                                                                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI = body mass index measured by weight (kg)/height (m^2^); BP = blood pressure; HbA1C = glycosylated haemoglobin; IR = insulin resistance; MetS = metabolic syndrome; T2DM = type 2 diabetes mellitus; TC = total cholesterol, TG = triglycerides; UA = uric acid.

^*∗*^ *Intervention duration* is the time the intervention was administered excluding any washout periods.

^*∗∗*^ *Participants* who completed the study are listed excluding any drop-outs.

^1^ *Tulasi Tablets* are product of Himalaya Herbal Healthcare Pharmaceutical Company in India.

^**2**^Tincture is a product of BM private limited.

^3^The quantity of tulsi fresh leaves was not specified; "handful" of leaves was given to each patient.

###### 

Effect of tulsi on immune system and viral infections in human clinical trials.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical\                            Authors\                               Study design          Jadad\           Participants^*∗∗*^ (age range)   Tulsi\                Intervention     Comparator        Outcome\                           Adverse\                       
  domain                               (year)                                                       score                                             extract                                                  measure(s)                         events (s)                     
  ------------------------------------ -------------------------------------- --------------------- ---------------- -------------------------------- --------------------- ---------------- ----------------- ---------------------------------- ------------------------------ ------
  Immunomodulation                     Venu Prasad (2014) \[[@B73]\]          Randomized,\          **3**            30 healthy\                      Ethanolic\            2 weeks          1 bar × 2/day\    Not described\                     ↑physical performance\         None
                                                                              placebo-controlled\                    adults\                          tulsi leaves\                          (1000 mg tulsi)   "control bar"                      ↓fatigue and CK levels\        
                                                                              clinical trial                         (18--30 years)                   in Bar^‡^                                                                                   less increase in lactic acid   

  Mondal^†^ et al. (2011) \[[@B72]\]   Randomized,\                           **5**                 22 healthy\      Ethanolic\                       4 weeks\              300 mg/day       Cellulose\        Increased cytokine level,\         None                           
                                       double-blind,\                                               adults\          tulsi leaves                     (+3 weeks wash out)                    300 mg/day        interferon-*ϒ*,  & interleukin-4                                  
                                       placebo-controlled\                                          (22--37 years)                                                                                                                                                               
                                       cross-over                                                                                                                                                                                                                                

  Sharma (1983) \[[@B82]\]             Open clinical trial                    **1**                 20 adults,\      Aqueous\                         1 week                500 mg × 3/day   None              Relief within 3 days,\             None                           
                                                                                                    asthma           tulsi leaves\                                                                             improved vital capacity                                           
                                                                                                                     tablets                                                                                                                                                     

                                                                                                                                                                                                                                                                                 

  Viral infections                     Rajalakshmi et al. (1986) \[[@B83]\]   Clinical trial        **0**            20 cases,\                       Aqueous\              2 weeks for\     10 g daily        None                               Symptoms all improved\         None
                                                                                                                     viral hepatitis\                 extract fresh\        mild cases\                                                           within 2 weeks                 
                                                                                                                     (10--60 years)                   tulsi leaves          3 weeks for\                                                                                         
                                                                                                                                                                            Severe cases                                                                                         

  Das et al. (1983) \[[@B77]\]         Randomized\                            **1**                 14 adults,\      Aqueous\                         4 weeks               2.5 g\           12 mg/day\        Increased survival rate\           Not\                           
                                       clinical trial\                                              viral\           extract fresh\                                         4 times/day      dexamethasone\    compared to steroid                reported                       
                                       parallel-controlled                                          encephalitis     tulsi leaves                                                            treated group                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CK = creatine kinase; TPE = tropical pulmonary eosinophilia.

^*∗*^ *Intervention duration* included wash-out periods where applicable until study was completed.

^*∗∗*^ *Participants* include both control and intervention groups completing the study and excluded any drop-outs.

^†^Same results as previously published (Mondal et al., 2010).

^‡^Tulsi enriched bar: each 25 g bar contained oats, resin, peanuts, skimmed milk powder, sugar, and honey and 0.5% ethanolic tulsi.

###### 

Therapeutic effects of tulsi on cognitive function, mood, and stress in human clinical trials.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical\                                Authors\                           Study design          Jadad\           Participants^*∗∗*^ (age range)   Tulsi\          Intervention   Comparator     Outcome\                 Adverse\                  
  domain                                   (year)                                                   score                                             extract                                       measure(s)               events (s)                
  ---------------------------------------- ---------------------------------- --------------------- ---------------- -------------------------------- --------------- -------------- -------------- ------------------------ ------------------------- ------
  Neurocognition                           Sampath et al. (2015) \[[@B71]\]   Randomized,\          **5**            40 healthy\                      Ethanolic\      4 weeks        300 mg/day\    Cellulose\               Cognitive flexibility,\   None
                                                                              double-blind,\                         adults\                          tulsi leaves\                  before meals   capsules                 attention, Improved\      
                                                                              placebo controlled\                    (18--30 years)                   capsules                                                               working memory\           
                                                                              clinical trial                                                                                                                                 only after day 15         

  Saxena et al. (2012) \[[@B69]\]          Randomized,\                       **4**                 150 adults,\     OCIBEST^†^  \                    6 weeks         400 mg\        Cellulose\     Reduction in stress\     None                      
                                           double-blind,\                                           stress\          whole plant\                                     3 times/day\   capsules       related symptoms:\                                 
                                           placebo-controlled                                       (18--65 years)   capsules                                         after meals                   fatigue, sleep and\                                
                                                                                                                                                                                                    sexual problems                                    

  Verma^‡^ et al. (2012) \[[@B68]\]        Clinical trial                     **0**                 24 adults,\      powder\                          12 weeks        3 g × 2/day    None           Reduced anxiety\         None                      
                                                                                                    psychosomatic\   whole plant\                                                                   significantly lowered\                             
                                                                                                    (60--80 years)   tulsi                                                                          biological age score                               

  Bhattacharyya et al. (2008) \[[@B84]\]   Clinical trial                     **1**                 35 adults\       Ethanolic\                       8 weeks         500 mg\        None           Self-reported\           None                      
                                                                                                    with GAD\        tulsi leaves\                                    2x daily\                     questionnaire,\                                    
                                                                                                    (18--60 years)   capsules                                         after meals                   ↓anxiety, stress, &\                               
                                                                                                                                                                                                    depression                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GAD = generalized anxiety disorder.

^*∗*^ *Intervention duration* is the time the intervention was administered excluding any washout periods.

^*∗∗*^ *Participants* include both control and intervention groups completing the study and excluded any drop-outs.

^†^ *OCIBEST* is product of natural remedies and contains tulsi whole plant.

^‡^Authors also reported findings from glucose and lipid profile for 5 of the participants and found lipid profile significantly improved.

[^1]: Academic Editor: Daniela Rigano
